Expensive cancer drugs: A comparison between the United States and the United Kingdom

Milbank Quarterly

Volumn 87, Issue 4, 2009, Pages 789-819

  Faden, Ruth R ^a   Chalkidou, Kalipso ^a   Appleby, John ^a   Waters, Hugh R ^a   Leider, Jonathon P ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Access; Affordability; Cancer drugs; Fairness; Prioritization; Priority setting; Rationing

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PATIENT; CONTROLLED STUDY; DRUG COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; NEOPLASM; REVIEW; UNITED KINGDOM; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST SHARING; DECISION MAKING; DRUG COSTS; FEES, PHARMACEUTICAL; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NEOPLASMS; PHARMACOPOEIAS AS TOPIC; UNITED STATES;

EID: 72449203777     PISSN: 0887378X     EISSN: 14680009     Source Type: Journal    
DOI: 10.1111/j.1468-0009.2009.00579.x     Document Type: Review

References (71)

1. Abelson, R., and A. Pollack. 2009. Medicare Widens Drugs It Accepts for Cancer. New York Times, January 26.
2. Alltucker, K. 2008. Ariz. Backs Insurers in Most Claim Disputes. Arizona Republic, November 2.
3. Appleby, J., and A. Alvarez-Rosete. 2005. Public Responses to NHS Reform. In British Social Attitudes: The 22nd Report, edited by A. Park, J. Curtice, K. Thomson, C. Bromley, M. Phillips, and M. Johnson, p. 109. London : Sage.
4. Arozullah, A.M., E.A. Calhoun, M. Wolf, D. Finley, K. Fitzner, E. Heckinger, N. Gorby, G. Schumock, and C. Bennett. 2004. The Financial Burden of Cancer: Estimates from a Study of Insured Women with Breast Cancer. Journal of Supportive Oncology 2 (3 271 278.
5. Associated Press. 2008. Drug Company Supplies Cancer Drug Oregon Health Plan Won't, June 3.
6. Atkinson, A.B. 1983. The Economics of Inequality. Oxford : Clarendon Press.
7. Bach, P.B. 2009. Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. New England Journal of Medicine 360 (6 626.
8. Berenson, A. 2008. Drug Plan's Side Effect Is Severe. New York Times, April 8.
9. Bosanquet, N., A. Haldenby, L. Hurley, F. Jolly, H. Rainbow, and K. Sikora. 2008. Making the NHS the Best Insurance Policy in the World. London : Reform. Available at http://www.reform.co.uk/Research/Health/HealthArticles/ tabid/80/smid/378/ArticleID/1/reftab/69/t/ Making%20the%20NHS%20the%20best%20insurance%20policy%20in%20the%20world/Default. aspx (accessed May 1, 2009).
10. Brock, D.W. 2002. Priority to the Worse Off in Health-Care Resource Prioritization. In Medicine and Social Justice: Essays on the Distribution of Health Care, edited by R. Rhodes, M. Baltin, and A. Silvers, p. 362. New York : Oxford University Press.
11. Chalkidou, K., J. Lord, A. Fischer, and P. Littlejohns. 2008. Evidence-Based Decision Making: When Should We Wait for More Information Health Affairs 27 (6 1642.
12. Centers for Medicare and Medicaid Services (CMS). 2005a. Breast and Cervical Cancer: Prevention and Treatment. Baltimore : CMS. Available at http://www.cms.hhs.gov/MedicaidSpecialCovCond/02-BreastandCervicalCancer- PreventionandTreatment.asp (accessed June 5, 2009).
13. Centers for Medicare & Medicaid Services (CMS). 2005b. Medicare Parts B/D Coverage Issues. Baltimore : CMS.
14. Coleman, M.P. 2007. Not Credible: A Subversion of Science by the Pharmaceutical Industry. Commentary on "A Global Comparison Regarding Patient Access to Cancer Drugs Annals of Oncology 18 (9 1433.
15. Coleman, M.P., M. Quaresma, F. Berrino, J. Lutz, R. De Angelis, R. Capocaccia, P. Baili, et al. 2008. Cancer Survival in Five Continents: A Worldwide Population-Based Study (CONCORD). Lancet Oncology 9 (8 730 756.
16. Connolly, C., and K. Marr. 2008. As Budgets Tighten, More People Decide Medical Care Can Wait. Washington Post, October 16.
17. Daniels, N. 2008. Just Health: Meeting Health Needs Fairly. Cambridge : Cambridge University Press.
18. Daniels, N., and J.E. Sabin. 2008. Accountability for Reasonableness: An Update. British Medical Journal 337 (October 9 a1850.
19. Department of Health. 2008. Draft Guidance on NHS Patients Who Wish to Pay for Additional Private Care. London : Crown. Available at http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH-089926 (accessed October 5, 2009).
20. Department of Health. 2009a. The NHS Constitution. London : Crown. Available at http://www.dh.gov.uk (accessed November 5, 2009).
21. Department of Health. 2009b. Uptake of NICE Approved Cancer Drugs 2007/2008. London : Crown. Available at http://www.dh.gov.uk/en/ Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH-098856 (accessed May 15, 2009).
22. Donaldson, C., and D. Ruta. 2005. Should the NHS Follow the American Way British Medical Journal 331 (7528 1328 1330.
23. Donelan, K. 2009. Overcoming Barriers to Cancer Care: Patient and Public Perspectives. In Toward the Elimination of Cancer Disparities, edited by H. Koh, pp. 299 315. New York : Springer.
24. Drummond, M., and A. Mason. 2009. Rationing New Medicines in the UK. British Medical Journal 338 (January 22 a3182.
25. Feachem, R.G.A., N.K. Sekhri, K.L. White, J. Dixon, D.M. Berwick, and A.C. Enthoven. 2002. Getting More for Their Dollar: A Comparison of the NHS with California's Kaiser Permanente; Commentary: Funding Is Not the Only Factor; Commentary: Same Price, Better Care; Commentary: Competition Made Them Do It. British Medical Journal 324 (7330 135 143. Available at http://www.bmj.com/cgi/ content/full/324/7330/135 (accessed October 6, 2009).
26. Fojo, T., and C. Grady. 2009. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Journal of the National Cancer Institute 101 : 1 5.
27. Furlow, B. 2009. US Cancer Centres Hit Hard by Deteriorating Economy. Lancet Oncology 10 (5 448 449.
28. Garber, A.M., and M.B. McClellan. 2007. Satisfaction Guaranteed - "Payment by Results" for Biologic Agents. New England Journal of Medicine 357 (16 1575.
29. Gatta, G., R. Capocaccia, M. Sant, C. Bell, J. Coebergh, R. Damhuis, J. Faivre, et al. 2000. Understanding Variations in Survival for Colorectal Cancer in Europe: A EUROCARE High Resolution Study. British Medical Journal 47 (4 533 538.
30. Gold, M.R. 1996. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press.
31. Gold, M.R., S. Sofaer, and T. Siegelberg. 2007. Medicare and Cost-Effectiveness Analysis: Time to Ask the Taxpayers. Health Affairs 26 (5 1399.
32. Kaa, K. 2007. Medicare Challenges and Solutions - Reimbursement Issues in Treating the Patient with Colorectal Cancer. Journal of Managed Care Pharmacy 13 (suppl. C, 6 S19 S26.
33. Kasemsup, V., J.C. Schommer, R.R. Cline, and R.S. Hadsall. 2008. Citizen's Preferences Regarding Principles to Guide Health-Care Allocation Decisions in Thailand. Value in Health 11 (7 1194 1202.
34. Kim, P. 2007. Cost of Cancer Care: The Patient Perspective. Journal of Clinical Oncology 25 (2 228.
35. Kolata, G. 2008. Costly Cancer Drug Offers Hope, but Also a Dilemma. New York Times, July 6.
36. Lee, T.H., and E.J. Emanuel. 2008. Tier 4 Drugs and the Fraying of the Social Compact. New England Journal of Medicine 359 (4 333.
37. Littlejohns, P., S. Garner, N. Doyle, F. Macbeth, D. Barnett, and C. Longson. 2009. 10 Years of NICE: Still Growing and Still Controversial. Lancet Oncology 10 (4 417 424.
38. McCabe, C., K. Claxton, and A.J. Culyer. 2008. The NICE Cost-Effectiveness Threshold: What It Is and What That Means. PharmacoEconomics 26 (9 733.
39. MedPAC. 2008. Payment Basics: Part D Payment System. Washington D.C. : MedPac. Available at http://www.medpac.gov/documents/MedPAC-Payment-Basics-08- PartD.pdf (accessed September 20, 2009).
40. Miller, T.E. 1998. Center Stage on the Patient Protection Agenda: Grievance and Appeal Rights. Journal of Law, Medicine & Ethics 26 (2 89 99.
41. Mooney, G. 1987. What Does Equity in Health Mean? [Qu'est-ce que l'équité en matière de santé?] World Health Statistics Quarterly Rapport trimestriel de statistiques sanitaires mondiales 40 (4 296 303.
42. Morone, J.A. 1992. The Bias of American Politics: Rationing Health Care in a Weak State. University of Pennsylvania Law Review 140 (5 1923 1938.
43. Mort, D., M. Lansdown, N. Smith, K. Protopapa, and M. Mason. 2008. For Better, for Worse? A Report by the National Confidential Enquiry into Patient Outcome and Death. London : National Confidential Enquiry into Patient Outcome and Death.
44. National Institute for Health and Clinical Excellence (NICE). 2006. NICE Citizens Council Report - Rule of Rescue No. 2009. London : Crown.
45. National Institute for Health and Clinical Excellence (NICE). 2008. Appraising Treatments Which May Extend Life, at the End of Life. London : Crown.
46. Nord, E. 1993. The Trade-off between Severity of Illness and Treatment Effect in Cost-Value Analysis of Health Care. Health Policy 24 (3 227 238.
47. Nord, E. 2005. Concerns for the Worse Off: Fair Innings versus Severity. Social Science & Medicine 60 (2 257 263.
48. Organisation for Economic Co-operation and Development (OECD). 2009. Health Data File 2009. Paris.
49. Pearson, S.D., and M.D. Rawlins. 2005. Quality, Innovation, and Value for Money: NICE and the British National Health Service. Journal of the American Medical Association 294 (20 2618 2622.
50. Pollack, A. 2009. As Pills Treat Cancer, Insurance Lags Behind. New York Times, April 14.
51. Powers, M., and R.R. Faden. 2006. Social Justice. New York : Oxford University Press.
52. Rachet, B., C. Maringe, U. Nur, M. Quaresma, A. Shah, L.M. Woods, L. Ellis, et al. 2009. Population-Based Cancer Survival Trends in England and Wales Up to 2007: An Assessment of the NHS Cancer Plan for England. Lancet Oncology 10 (4 351 369.
53. Rawlins, M.D., and A.J. Culyer. 2004. National Institute for Clinical Excellence and Its Value Judgments. British Medical Journal 329 (7459 224 227.
54. Reinhardt, U.E., P.S. Hussey, and G.F. Anderson. 2004. U.S. Health Care Spending in an International Context. Health Affairs 23 (3 10 25.
55. Richards, M. 2006. Usage of Cancer Drugs Approved by NICE: Report of Review Undertaken by the National Cancer Director. London : Department of Health.
56. Richards, M. 2008. Improving Access to Medicines for NHS Patients. London : Department of Health.
57. Sant, M., C. Allemani, R. Capocaccia, T. Hakulinen, T. Aareleid, J. Coebergh, M. Coleman, et al. 2003. Stage at Diagnosis Is a Key Explanation of Differences in Breast Cancer Survival across Europe. International Journal of Cancer 107 (6 416 422.
58. Schwartz, K., G. Claxton, K. Martin, and C. Schmidt. 2009. Spending to Survive: Cancer Patients Confront Holes in the Health Insurance System. Menlo Park, Calif Kaiser Family Foundation and American Cancer Society.
59. Summer, L., J. Hoadley, E. Hargrave, J. Cubanski, and T. Neuman. 2009. Medicare Part D 2009 Data Spotlight: Low-Income Subsidy Plan Availability. Baltimore : Kaiser Family Foundation.
60. Szabo, L. 2008. Study: Many Cancer Patients Forgoing Care Because of Cost. USA Today, October 13.
61. Tapay, N., and F. Colombo. 2004. Private Health Insurance in OECD Countries: The Benefits and Costs for Individuals and Health Systems. In Towards High-Performing Health Systems: Policy Studies, edited by E. Docteur, pp. 265 319. Paris : OECD.
62. Thorpe, K.E., and D. Howard. 2003. Health Insurance and Spending among Cancer Patients. Health Affairs 3 : 189 198.
63. Tyler, R. 2008. The Maryland Insurance Administration's 2007 Report on the Health Care Appeals & Grievance Law. Baltimore : Maryland Insurance Administration.
64. Ubel, P.A. 2001. Pricing Life: Why It's Time for Health Care Rationing. Cambridge, Mass. : MIT Press.
65. Ubel, P.A., R.M. Arnold, and A.L. Caplan. 1993. Rationing Failure: The Ethical Lessons of the Retransplantation of Scarce Vital Organs. Journal of the American Medical Association 270 (20 2469 2474.
66. Veatch, R.M. 1999. Justice, the Basic Social Contract, and Health Care. In Contemporary Issues in Bioethics, 5th ed., edited by T. Beauchamp and L. Walters, pp. 368 374. Belmont, Calif. : Wadsworth.
67. Ward, E., M. Halpern, N. Schrag, V. Cokkinides, C. DeSantis, P. Bandi, R. Siegel, A. Stewart, and A. Jemal. 2008. Association of Insurance with Cancer Care Utilization and Outcomes. CA: A Cancer Journal for Clinicians 58 (1 9.
68. Waters, H.R. 2000. Measuring Equity in Access to Health Care. Social Science & Medicine 51 (4 599 612.
69. Webster, C. 2002. The National Health Service: A Political History. New York : Oxford University Press.
70. Wilson, D. 2009. Waxman Takes on Drug Makers Over Medicare. New York Times, August 25. Available at http://www.nytimes.com/2009/08/26/health/policy/ 26dual.html (accessed October 6, 2009).
71. Yabroff, K.R., J.L. Warren, and M.L. Brown. 2007. Costs of Cancer Care in the USA: A Descriptive Review. Nature Clinical Practice Oncology 4 (11 643 656.